PentaBase takes another leap forward with the appointment of…
CEO Ulf Bech Christensen (middle) welcomes Simon Rye Clausen (left), Henrik Schmidt (right) and Matilde Forcella (below) to the PentaBase board.
As part of PentaBase´s efforts to consolidate the market acceptance of our real-time PCR-based assays with game-changing sensitivity, the company has strengthened the organization in general and the Board of Directors in particular to focus the strategy of the company moving forward. Thus, the PentaBase Board has gained important experience by appointing three new Directors:
Simon Rye Clausen, MD
Simon has over 30 years of experience from the pharma industry. He has worked in Roche, Pfizer, Indivior and Eli Lilly pharmaceuticals, as well as being general manager of Life Technologies in Denmark. Simon was the original founder and CEO of the biotech company Genesto A/S and has serial experience in life-science start-up bridging into market opportunities of improved sales and marketing capabilities.
“I am excited by PentaBase and its technologies and solutions, which help patients with a disease specific genetic profile to get better treatment. Their products seem game-changing and set their own higher standard – while at the same time simply can be used on most PCR-platforms”, says Simon Rye Clausen, Chairman of the Board of Directors at PentaBase.
Henrik Schmidt, MBA
Henrik has worked 25 years in international business of medical diagnostics and devices, predominantly in Roche Diabetes Care and Medtrum Tech. Furthermore, Henrik has been involved in successful entrepreneurial businesses throughout his career.
“I see plenty of opportunities to engage with collaborators around the Globe with the easy-to-apply PentaBase assays to ensure optimized treatment to the individual patients for the benefit of the patient, relatives and payors hereby using scarce healthcare resources intelligently”, says Henrik Schmidt
Matilde Forcella, PhD
Matilde has a background as a PhD in biochemistry from the university in Milan and has published extensively in the field of carcinogenesis. Currently, Matilde works as a post-doc in the university of Milan-Bicocca.
“PentaBase products are easily applied to all types of materials (tissues, liquid biopsies) with unprecedented sensitivity”, says Matilde Forcella.
The three Directors are developing the PentaBase strategy with the management team and its advisors, and wish to further strengthen the platform of knowledge and experience with quality diagnostic assays integrated at full into the clinical reality of patients’ lives.
